Nivea launches its €17.99 anti-ageing night cream that works while you sleep
At €17.99, can a night cream genuinely act on the mechanisms of skin ageing? That is the challenge Nivea is taking on in 2026 with a new nocturnal formula, designed to work in sync with the skin’s natural recovery cycle.
A night treatment built around skin longevity
The Cellular Epigenetics Youth Night Cream is not simply a nocturnal spin-off of the iconic blue tin. The brand developed this product off the back of several years of research dedicated to skin ageing. Its stated ambition goes well beyond standard hydration: the goal is to target five visible signs of ageing while reinforcing the skin’s protective barrier.
To achieve this, the formula relies on a patented active ingredient called Epicelline®, born from more than fifteen years of research into epigenetics. According to the brand, this ingredient is designed to reactivate the skin cells’ youthful functions. This positioning clearly sets the new cream apart from the legendary blue pot, whose primary purpose remains nourishment.
Night-time is a strategic moment in this approach. It is during sleep that the skin undergoes an intense phase of regeneration. The cream has therefore been formulated to integrate with these natural mechanisms, rather than simply masking the visible effects of time.
What is actually inside the Nivea formula
In this night version, Epicelline® is paired with provitamin B5. This combination aims to support cellular regeneration while contributing to the reinforcement of the skin barrier. The choice of provitamin B5 reflects a holistic skincare logic that goes beyond reducing fine lines to also preserving the skin’s natural resilience.
The brand has also developed a patented technology called Age Clock®, presented as a tool for measuring the biological age of the skin. This approach illustrates the philosophy claimed by Beiersdorf, the group that owns Nivea: focusing on the causes of ageing rather than its purely aesthetic consequences.
- Key active ingredient: Epicelline®, patented after more than fifteen years of epigenetics research
- Associated ingredient: provitamin B5
- Targets five visible signs of ageing
- Age Clock® technology to measure the biological age of the skin
- Skin barrier reinforcement included among the claimed benefits
An accessible price point that changes the game
The price is one of the most compelling arguments for this launch. At €17.99, the Cellular Epigenetics Youth Night Cream stays well under the €18 mark. For consumers who want to add a targeted night treatment to their routine without spending several tens of euros, this positioning offers a genuine alternative to premium products.
This pricing decision is consistent with the mass-market identity Nivea is determined to maintain. The brand is not sacrificing its historic accessibility, even while putting forward a formula that claims patented technologies and years of in-depth research. Dr Gitta Neufang, Director of Research and Development at Beiersdorf, sums up this direction: the group says it is convinced that the right approach is to act at the root cause of skin ageing, rather than settling for immediate cosmetic effects.
The blue cream stays, but the range grows
This launch adds to the existing Cellular Epigenetics line and also shows how Nivea is looking to modernise its image without abandoning its popular positioning. The brand is responding to a shift in expectations: some consumers are now seeking products capable of targeting the signs of ageing more precisely, beyond everyday hydration alone.
That said, the iconic blue cream retains its rightful place for those who love its nourishing power. The two products coexist within an expanded offering, each addressing different needs. The notion of skin longevity, now central to the brand’s messaging, reflects an ambition to preserve the skin’s long-term functioning by providing active ingredients suited to its real needs.
